Institution led by Weidong Han

Cart-Gen Therapeutics is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative chimeric antigen receptor T-cell (CAR-T) therapies. The company was founded and is led by Dr. Weidong Han, a prominent figure in oncology and the Director of Bio-therapeutics at the Chinese PLA General Hospital. Cart-Gen focuses on advancing cell therapies for both hematological malignancies and difficult-to-treat solid tumors, utilizing proprietary platforms to enhance T-cell persistence and tumor infiltration. Their pipeline features several clinical-stage candidates targeting antigens such as CD19, CD20, BCMA, and EGFR. By integrating deep clinical insights with cutting-edge genetic engineering, Cart-Gen aims to provide curative options for cancer patients globally. The company is recognized for its pioneering work in multi-target CAR-T designs and its extensive clinical trial network within China.